Update on the current status of peptide immunotherapy
Author:
- 1 April 2007
- journal article
- review article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 119 (4) , 906-909
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Peptide therapy for allergic diseases: Basic mechanisms and new clinical approachesPharmacology & Therapeutics, 2005
- Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjectsClinical & Experimental Allergy, 2005
- Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled studyAllergy, 2004
- Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trialThe Lancet, 2002
- Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic SubjectsThe Journal of Immunology, 2001
- The Safety and Efficacy of ALLERVAX CAT in Cat Allergic PatientsClinical Immunology, 1999
- Immunoglobulin E–independent Major Histocompatibility Complex–restricted T Cell Peptide Epitope–induced Late Asthmatic ReactionsJournal of Experimental Medicine, 1999
- Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to catsJournal of Allergy and Clinical Immunology, 1998
- Treatment of Cat Allergy With T-Cell Reactive PeptidesAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjectsInternational Immunology, 1996